Directors screw-ups lead to Lost Business

[Anonymous]

Yet they still give themselves bonuses and pay raises.



Business has benefited from problems of Hospira


http://www.fiercepharmamanufacturing.com/story/hikma-will-keep-injectable-manufacturing/2013-04-18


For the last several years the business model for Hikma's injectable drug business has gone something like this: Market leader Hospira ($HSP) reports a problem and Hikma picks up more business. The strategy has worked so well that the company says it will keep the rapidly growing division despite the fact big drugmakers are interested in buying it, and analysts say it might fetch up to $2 billion.



Read more: Hikma will keep injectables manufacturing - FiercePharma Manufacturing http://www.fiercepharmamanufacturin...ctable-manufacturing/2013-04-18#ixzz2QuhT0jXN

 

[Anonymous]

Can't make a quality product to sell, so they try to sue other businesses for theirs.


http://blogs.marketwatch.com/health...hares-leap-late-after-ruling-on-patent-cases/



Cubist officials said that U.S. District Court Judge Gregory M. Sleet ruled in favor of the company in a Delaware court, where it was defending itself in a patent challenge from Hospira Inc

 

[Anonymous]

See the above...whoops ...below re: ACC

 

[Anonymous]

Yet they still give themselves bonuses and pay raises.



Business has benefited from problems of Hospira


http://www.fiercepharmamanufacturing.com/story/hikma-will-keep-injectable-manufacturing/2013-04-18


For the last several years the business model for Hikma's injectable drug business has gone something like this: Market leader Hospira ($HSP) reports a problem and Hikma picks up more business. The strategy has worked so well that the company says it will keep the rapidly growing division despite the fact big drugmakers are interested in buying it, and analysts say it might fetch up to $2 billion.



Read more: Hikma will keep injectables manufacturing - FiercePharma Manufacturing http://www.fiercepharmamanufacturin...ctable-manufacturing/2013-04-18#ixzz2QuhT0jXN

Peon,
We are not worried about lost business. We ARE concerned about options under water.
And how to fix that. We need Mr. Begley back. Now.
You go back to work and appreciate you have a job.

 

[Anonymous]

Peon,
We are not worried about lost business. We ARE concerned about options under water.
And how to fix that. We need Mr. Begley back. Now.
You go back to work and appreciate you have a job.

whats you got boy see you posting on memorial day like the loser you are so answer my question

 

[Anonymous]

For the last several years the business model for Hikma's injectable drug business has gone something like this: Market leader Hospira ($HSP) reports a problem and Hikma picks up more business. The strategy has worked so well that the company says it will keep the rapidly growing division despite the fact big drugmakers are interested in buying it, and analysts say it might fetch up to $2 billion.

That is Hikma's only strategy for the injectibles business, as told to us in Cherry Hill directly from the top. Wait for competitor to have FDA/manufacturing issues, jump in for the short term to take over the sales, concede sales when competitor recovers, repeat process. There is no strategy to grow the business, just feast on the short term ills of others when you can charge significantly higher prices.